Study: Cannabidiol Shows Potential to Target Key Drivers of Diabetic Heart Disease

A study published in Biomedicine & Pharmacotherapy reports cannabidiol (CBD) may help address multiple underlying mechanisms involved in diabetic heart disease.

Conducted by researchers from Bowen University, North-West University, Nelson Mandela University, and the University of the Western Cape, the review highlights CBD’s potential to impact several pathways linked to cardiovascular complications in people with diabetes.

According to the findings, preclinical studies show that CBD may reduce oxidative stress, suppress inflammation, and limit fibrotic remodeling in heart tissue. These processes are central to diabetic heart disease, which is driven by metabolic dysfunction, chronic inflammation, and vascular damage.

The research notes that CBD appears to lower the production of reactive oxygen species and inhibit inflammatory signaling pathways such as NF-κB, while also improving endothelial function by increasing nitric oxide availability. In animal models, these effects were associated with improved heart function and reduced tissue damage.

CBD’s mechanisms are described as multi-target, involving both cannabinoid-related activity—such as modulation of CB1 receptors—and interactions with other systems including TRPV1, PPARγ, and GPR55. These combined effects may help explain its potential role in addressing complex conditions like diabetic cardiomyopathy.

Despite these promising findings, researchers emphasize that evidence in humans is lacking. Existing clinical studies have largely focused on general cardiovascular markers or non-diabetic populations, and have not directly examined outcomes related to diabetic heart disease.

“Diabetic heart disease remains a major contributor to global morbidity, driven by intersecting metabolic, inflammatory, and fibrotic pathways that are not fully addressed by current cardiometabolic therapies. In this context, cannabidiol (CBD) has emerged as a mechanistically compelling investigational candidate”, states the study. “Specifically, preclinical studies demonstrate that CBD actively modifies key molecular drivers of DHD.”

They continue by saying “In vitro, CBD reduces high-glucose-induced reactive oxygen species (ROS) generation and suppresses NF-κB activation in human cardiomyocytes and endothelial cells, thereby preserving cellular viability and barrier integrity. In vivo studies in streptozotocin-induced diabetic cardiomyopathy (DbCM) and Zucker diabetic fatty rat models show that CBD attenuates myocardial oxidative stress, downregulates TGF-β- mediated fibrotic remodeling, and improves endothelium-dependent vasodilation.”

These effects “translate into measurable improvements in both systolic and diastolic function. Mechanistically, CBD exerts these actions through negative allosteric modulation of CB₁ receptors, as well as engagement of non-cannabinoid targets, including TRPV1, PPARγ, and GPR55.”

Researchers say that “Despite this robust preclinical foundation, translation of these mechanistic insights into clinical benefit remains unproven. Current human data are limited to short-term hemodynamic assessments in non-diabetic populations or isolated metabolic endpoints, with no randomized controlled trials evaluating CBD in the context of DHD. Furthermore, key translational challenges persist, including cytochrome P450-mediated drug-drug interactions within cardiovascular polypharmacy, lack of standardized dosing regimens, and variability in product quality and regulatory oversight.”

The full study can be found by clicking here, and the study’s full abstract can be found below:

Abstract

Diabetic heart disease (DHD) is a major contributor to global cardiovascular morbidity, driven by a complex interplay of metabolic, inflammatory, oxidative, and fibrotic mechanisms. These interconnected pathways are not fully addressed by current cardiometabolic therapies, highlighting the need for novel multi-target interventions. Cannabidiol (CBD), a non-psychoactive phytocannabinoid, has emerged as a potential modulator of several key processes implicated in DHD pathogenesis. Preclinical evidence demonstrates that CBD attenuates oxidative stress by reducing reactive oxygen species (ROS) production, suppresses nuclear factor-κB (NF-κB)-mediated inflammatory signaling, preserves endothelial function by improving nitric oxide (NO) bioavailability, and inhibits transforming growth factor-β (TGF-β)-driven fibrotic remodeling. These effects have been observed across in vitro and in vivo models of diabetic cardiomyopathy, where CBD improves both myocardial and vascular function. Mechanistically, CBD exerts its actions through negative allosteric modulation of CB₁ receptors and interaction with non-cannabinoid targets, including transient receptor potential vanilloid 1 (TRPV1), peroxisome proliferator-activated receptor gamma (PPARγ), and G protein-coupled receptor 55 (GPR55). Despite this robust preclinical foundation, clinical evidence supporting the efficacy of CBD in DHD remains limited. Existing human studies are largely restricted to non-diabetic populations or short-term metabolic and hemodynamic outcomes, and do not address disease-specific cardiac endpoints. Furthermore, translational challenges, including variability in dosing, product standardization, and potential drug-drug interactions, remain significant barriers to clinical implementation. Collectively, CBD represents a promising investigational candidate with multi-target potential to modulate the core pathophysiology of DHD. However, well-designed, disease-specific clinical trials are required to establish its therapeutic relevance and safety in diabetic populations.